Published in Am J Epidemiol on July 25, 2016
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (2000) 15.40
Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA (2009) 7.78
Immortal time bias in pharmaco-epidemiology. Am J Epidemiol (2007) 6.98
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA (2012) 5.11
New natural history of interferon-beta-treated relapsing multiple sclerosis. Ann Neurol (2007) 3.87
A linear regression model for the analysis of life times. Stat Med (1989) 3.75
Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf (2007) 3.66
Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ (2010) 3.09
Immortal time bias in critical care research: application of time-varying Cox regression for observational cohort studies. Crit Care Med (2009) 2.96
Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med (2003) 2.90
Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol (2004) 2.70
Do OSCAR winners live longer than less successful peers? A reanalysis of the evidence. Ann Intern Med (2006) 2.46
Disability progression in multiple sclerosis is slower than previously reported. Neurology (2006) 2.40
Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies. Kidney Int (2011) 2.10
Statins and cancer risk. Am J Med (2008) 2.09
The relationship of blood product ratio to mortality: survival benefit or survival bias? J Trauma (2009) 2.03
Impact of multiple sclerosis relapses on progression diminishes with time. Neurology (2009) 1.86
A sequential stratification method for estimating the effect of a time-dependent experimental treatment in observational studies. Biometrics (2006) 1.63
Inhaled corticosteroids in chronic obstructive pulmonary disease: results from two observational designs free of immortal time bias. Am J Respir Crit Care Med (2005) 1.60
Long-term outcome in patients with ST segment elevation myocardial infarction and multivessel disease treated with culprit-only, immediate, or staged multivessel percutaneous revascularization strategies: Insights from the REAL registry. Catheter Cardiovasc Interv (2014) 1.54
Further results on the non-parametric linear regression model in survival analysis. Stat Med (1993) 1.53
Does cardiac transplantation prolong life? A reassessment. Ann Intern Med (1972) 1.48
Utilization patterns and patient outcomes associated with use of rescue therapies in acute lung injury. Crit Care Med (2011) 1.46
Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods. Am J Epidemiol (2005) 1.44
Accuracy of conventional and marginal structural Cox model estimators: a simulation study. Int J Biostat (2010) 1.30
Quantifying the impact of survivor treatment bias in observational studies. J Eval Clin Pract (2006) 1.28
An easy mathematical proof showed that time-dependent bias inevitably leads to biased effect estimation. J Clin Epidemiol (2008) 1.22
The impact of time-dependent bias in proportional hazards modelling. Stat Med (2008) 1.18
On the relationship between response to treatment and survival time. Stat Med (1996) 1.15
Time-dependent study entries and exposures in cohort studies can easily be sources of different and avoidable types of bias. J Clin Epidemiol (2012) 1.13
Armitage lecture 2010: Understanding treatment effects: the value of integrating longitudinal data and survival analysis. Stat Med (2012) 1.07
Comparison of algorithms to generate event times conditional on time-dependent covariates. Stat Med (2008) 1.02
A sequential Cox approach for estimating the causal effect of treatment in the presence of time-dependent confounding applied to data from the Swiss HIV Cohort Study. Stat Med (2010) 1.00
Effectiveness of antiresorptive agents in the prevention of recurrent hip fractures. Osteoporos Int (2007) 0.99
Evaluation of Cox's model and logistic regression for matched case-control data with time-dependent covariates: a simulation study. Stat Med (2003) 0.95
Simulation of survivorship bias in observational studies on plasma to red blood cell ratios in massive transfusion for trauma. Br J Surg (2012) 0.92
Clopidogrel and long-term outcomes after stent implantation for acute coronary syndrome. Am Heart J (2007) 0.92
Survivor treatment bias, treatment selection bias, and propensity scores in observational research. J Clin Epidemiol (2010) 0.88
Immortal time bias in the study of effectiveness of interferon-beta in multiple sclerosis. Ann Neurol (2008) 0.84
Analyzing direct and indirect effects of treatment using dynamic path analysis applied to data from the Swiss HIV Cohort Study. Stat Med (2011) 0.82
The effectiveness of beta-blockers in women with congestive heart failure. J Gen Intern Med (2007) 0.81
Investigation of heterogeneity in the association between interferon beta and disability progression in multiple sclerosis: an observational study. Eur J Neurol (2013) 0.80
Multiple sclerosis in older adults: the clinical profile and impact of interferon Beta treatment. Biomed Res Int (2015) 0.80
Comparison of methods for estimating the effect of salvage therapy in prostate cancer when treatment is given by indication. Stat Med (2013) 0.78
Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. Am J Epidemiol (2014) 0.78
Angiotensin-converting enzyme inhibitors and survival in women and men with heart failure. Eur J Heart Fail (2007) 0.78
Hormone replacement therapy and mid-term implant survival following knee or hip arthroplasty for osteoarthritis: a population-based cohort study. Ann Rheum Dis (2014) 0.78
Prediction of individual combined benefit and harm for patients with atrial fibrillation considering warfarin therapy: a study protocol. BMJ Open (2015) 0.77
Beta-interferon exposure and onset of secondary progressive multiple sclerosis. Eur J Neurol (2015) 0.76
Can joint replacement reduce cardiovascular risk? BMJ (2013) 0.76
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA (2012) 5.11
Longitudinal follow-up of "benign" multiple sclerosis at 20 years. Neurology (2007) 2.39
Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol (2010) 2.07
Expanding access to HAART: a cost-effective approach for treating and preventing HIV. AIDS (2010) 2.04
The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2010) 1.89
Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler (2011) 1.57
Natural, innate improvements in multiple sclerosis disability. Mult Scler (2012) 1.50
Bayesian sensitivity analysis for unmeasured confounding in observational studies. Stat Med (2007) 1.44
Air pollution and daily mortality in a city with low levels of pollution. Environ Health Perspect (2003) 1.39
Bayesian propensity score analysis for observational data. Stat Med (2009) 1.39
Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol (2010) 1.37
Neonatal intensive care unit characteristics affect the incidence of severe intraventricular hemorrhage. Med Care (2006) 1.25
Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology (2012) 1.17
Mental comorbidity and multiple sclerosis: validating administrative data to support population-based surveillance. BMC Neurol (2013) 1.17
Is probabilistic bias analysis approximately Bayesian? Epidemiology (2012) 1.16
A sensitivity analysis using information about measured confounders yielded improved uncertainty assessments for unmeasured confounding. J Clin Epidemiol (2007) 1.11
Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol (2013) 1.08
Accounting for independent nondifferential misclassification does not increase certainty that an observed association is in the correct direction. Am J Epidemiol (2006) 1.08
Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother (2013) 1.07
Rising prevalence of vascular comorbidities in multiple sclerosis: validation of administrative definitions for diabetes, hypertension, and hyperlipidemia. Mult Scler (2012) 1.07
Air pollution and cardiac arrhythmias in patients with implantable cardioverter defibrillators. Inhal Toxicol (2004) 1.06
The utility of administrative data for surveillance of comorbidity in multiple sclerosis: a validation study. Neuroepidemiology (2012) 1.05
A case-crossover analysis of particulate air pollution and cardiac arrhythmia in patients with implantable cardioverter defibrillators. Inhal Toxicol (2004) 1.05
Regression B-spline smoothing in Bayesian disease mapping: with an application to patient safety surveillance. Stat Med (2007) 1.04
Cancer risk in multiple sclerosis: findings from British Columbia, Canada. Brain (2012) 1.03
MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. Nat Rev Neurol (2011) 1.03
Bayesian analysis of a matched case-control study with expert prior information on both the misclassification of exposure and the exposure-disease association. Stat Med (2009) 1.03
The natural history of primary progressive multiple sclerosis. Neurology (2009) 1.02
Estimation in Bayesian disease mapping. Biometrics (2004) 0.97
Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler (2011) 0.97
Long-term persistence with the immunomodulatory drugs for multiple sclerosis: a retrospective database study. Clin Ther (2012) 0.96
The incidence and prevalence of multiple sclerosis in nova scotia, Canada. Can J Neurol Sci (2013) 0.94
Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression. Mult Scler (2012) 0.91
Hospital admissions and MS: temporal trends and patient characteristics. Am J Manag Care (2012) 0.90
Pelvic bone asymmetry in 323 study participants receiving abdominal CT scans. Spine (Phila Pa 1976) (2003) 0.90
Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 0.90
Hierarchical priors for bias parameters in Bayesian sensitivity analysis for unmeasured confounding. Stat Med (2012) 0.89
What do measures of agreement (κ) tell us about quality of exposure assessment? Theoretical analysis and numerical simulation. BMJ Open (2013) 0.87
A critical appraisal of risk models for predicting sexually transmitted infections. Sex Transm Dis (2014) 0.86
Neonatal and delivery outcomes in women with multiple sclerosis. Ann Neurol (2011) 0.86
An innovative application of Bayesian disease mapping methods to patient safety research: a Canadian adverse medical event study. Stat Med (2006) 0.86
Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci (2010) 0.85
Bayesian adjustment for exposure misclassification in case-control studies. Stat Med (2010) 0.85
The effect of smoking on the symptoms and progression of multiple sclerosis: a review. J Inflamm Res (2010) 0.84
Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol (2014) 0.84
Deriving and validating a risk estimation tool for screening asymptomatic chlamydia and gonorrhea. Sex Transm Dis (2014) 0.83
The psychosocial and cognitive impact of longstanding 'benign' multiple sclerosis. Mult Scler (2011) 0.83
Investigations of gene-disease associations: costs and benefits of environmental data. Epidemiology (2013) 0.82
The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. Neuroepidemiology (2012) 0.82
Retinal nerve fiber layer thickness in benign multiple sclerosis. Mult Scler (2013) 0.82
A Bayesian multilevel model for estimating the diet/disease relationship in a multicenter study with exposures measured with error: the EPIC study. Stat Med (2008) 0.82
Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology (2013) 0.82
Children and adolescents adjustment to parental multiple sclerosis: a systematic review. BMC Neurol (2014) 0.82
Bayesian adjustment for measurement error in continuous exposures in an individually matched case-control study. BMC Med Res Methodol (2011) 0.82
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open (2014) 0.80
A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs (2014) 0.80
Impact of outcome model misspecification on regression and doubly-robust inverse probability weighting to estimate causal effect. Int J Biostat (2010) 0.80
Birth outcomes in newborns fathered by men with multiple sclerosis exposed to disease-modifying drugs. CNS Drugs (2014) 0.80
Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis. Ann Neurol (2008) 0.79
The EHR's impact on HIM functions. J AHIMA (2005) 0.79
Obstetrical epidural and spinal anesthesia in multiple sclerosis. J Neurol (2013) 0.79
Interferons and multiple sclerosis: is it plausible that beta-IFN treatment could influence the risk of cancer among MS patients? Expert Rev Neurother (2009) 0.79
Characteristics of multiple sclerosis in aboriginals living in British Columbia, Canada. Mult Scler (2012) 0.78
A Bayesian method for estimating prevalence in the presence of a hidden sub-population. Stat Med (2012) 0.78
Risk prediction in sexual health contexts: protocol. JMIR Res Protoc (2013) 0.78
Marginal structural Cox models for estimating the association between β-interferon exposure and disease progression in a multiple sclerosis cohort. Am J Epidemiol (2014) 0.78
Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology (2013) 0.77
Defining the natural history of MS: the need for complete data and rigorous definitions. Mult Scler (2008) 0.77
Its okay to be a quad: wheelchair rugby players sense of community. Adapt Phys Activ Q (2009) 0.76
Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis. Neurology (2005) 0.76
What went wrong in the natalizumab trials Comment? Lancet (2006) 0.76
Multiple sclerosis and pregnancy: what should we be telling our patients? Neurology (2009) 0.76
A comparison of Bayesian hierarchical modeling with group-based exposure assessment in occupational epidemiology. Stat Med (2013) 0.75
The risks for falls and fractures in multiple sclerosis. Neurology (2012) 0.75
Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology (2005) 0.75
Pediatric bladder neuroblastoma: Case report and literature review. Can Urol Assoc J (2013) 0.75
Covariate balance in a Bayesian propensity score analysis of beta blocker therapy in heart failure patients. Epidemiol Perspect Innov (2009) 0.75
Association between beta-interferon exposure and hospital events in multiple sclerosis. Pharmacoepidemiol Drug Saf (2014) 0.75
EHR career opportunities: sample HIM job descriptions. J AHIMA (2005) 0.75
Disease-Modifying Therapies and Adherence in Multiple Sclerosis: Comparing Patient Self-Report with Pharmacy Records. Neuroepidemiology (2017) 0.75
Bayesian adjustment for covariate measurement errors: a flexible parametric approach. Stat Med (2009) 0.75
Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for multiple sclerosis. Neurology (2002) 0.75
Partial identification arising from nondifferential exposure misclassification: how informative are data on the unlikely, maybe, and likely exposed? Int J Biostat (2012) 0.75
Characteristics associated with drug-induced liver injury from interferon beta in multiple sclerosis patients. Expert Opin Drug Saf (2014) 0.75
Bayesian methods in survival analysis. Lifetime Data Anal (2010) 0.75
A flexible mixed-effect negative binomial regression model for detecting unusual increases in MRI lesion counts in individual multiple sclerosis patients. Stat Med (2015) 0.75